A 30-year-old man with obesity and longstanding type 2 diabetes comes in for a routine follow-up. His glycemic control remains poor despite treatment. As the visit unfolds, his physician notices persistent adult-onset acne. Years ago, the encounter might have ended there. Today, I imagine asking another question: “Does anyone in your family have what we used to call polycystic ovary syndrome?” His sister does.

That answer does not diagnose him with polyendocrine metabolic ovarian syndrome (PMOS), nor does it suggest a different treatment plan. But it may encourage the clinician to think differently about the broader metabolic picture. Rather than viewing obesity, diabetes, and endocrine findings as unrelated conditions, the physician might consider whether they reflect a familial pattern of a metabolic disorder that deserves closer attention.

That question has become part of how I teach. When the international consensus panel recommended renaming polycystic ovary syndrome (PCOS) as polyendocrine metabolic ovarian syndrome (PMOS) earlier this year, most of the discussion focused on the new terminology. Was the new name more accurate? Would clinicians adopt it? Would patients understand it?

As I read the consensus statement, I found myself thinking less about the name than about my own teaching. For years, I taught PCOS the same way many clinicians learned it: as a syndrome defined by hyperandrogenism, ovulatory dysfunction, and polycystic ovaries. A disease found only in women. Those features remain central to the diagnosis. But as the research continued to evolve, I realized my teaching had not fully kept pace with the broader metabolic story emerging from the evidence.

The PMOS consensus prompted me to reconsider what I emphasize when teaching future health care professionals. Today, I spend more time discussing its broader metabolic implications, including the role family history can play in recognizing patterns of disease. That shift has less to do with adopting a new acronym than with adopting a broader clinical framework.

Over the past two decades, evidence has increasingly demonstrated that metabolic dysfunction is central to this syndrome rather than simply an associated finding. Several studies have reported that first-degree male relatives of women with PMOS have higher rates of insulin resistance, type 2 diabetes, dyslipidemia, visceral obesity, and metabolic syndrome than the general population. Other studies have described associations with infertility and additional endocrine abnormalities among some male relatives.

These findings do not mean that men have PMOS. Nor do they justify new screening recommendations or changes to current clinical guidelines. They do, however, make me wonder whether we sometimes overlook clinically useful information by failing to ask about PMOS in the family history.

I am not suggesting that every patient with diabetes or obesity should now be evaluated through the lens of PMOS. The evidence does not support that conclusion. Rather, I am suggesting that in selected patients with complex metabolic or endocrine presentations, a family history of PMOS may deserve the same thoughtful consideration we already give to family histories of premature cardiovascular disease, hereditary cancers, or diabetes.

Family history remains one of the most valuable tools in medicine. Often, the questions we ask determine the patterns we recognize. We routinely ask about premature cardiovascular disease, hereditary cancers, diabetes, and numerous inherited disorders because those answers help us interpret the patient sitting in front of us. The PMOS consensus made me wonder whether, in selected patients with metabolic disease or endocrine abnormalities, a family history of PMOS deserves similar consideration.

That is not a recommendation. It is a question, one I think deserves more attention than it has received. For me, the PMOS consensus reinforced a broader lesson that extends well beyond this condition.

Medicine evolves incrementally. Our understanding of disease changes as evidence accumulates. Yet our diagnostic habits and teaching often evolve more slowly than the science itself.

As educators, we have a responsibility to prepare students not only to memorize today’s diagnostic criteria but also to recognize when those frameworks begin to expand. As clinicians, we should remain willing to ask whether new evidence warrants asking different questions during a patient encounter.

The long-term impact of the PMOS consensus will not be determined by how quickly clinicians replace one acronym with another. Its greater contribution may be encouraging us to think more broadly about metabolic disease, familial risk, and the clinical questions that shape our diagnostic reasoning.

For me, it began with one simple question I now spend more time teaching than I once did: “What does this patient’s family history tell me that I haven’t thought to ask?”

Jan Hinnen is a physician educator.